Everything below concerns reverse-phase HPLC. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-10-18. Where a claim depends on a specific study, the study is described rather than over-claimed.
The peptide binds GHRH receptors on somatotroph cells within the anterior pituitary, triggering a signalling cascade that increases growth hormone secretion. Its improved resistance to dipeptidyl peptidase IV degradation distinguishes it from the parent hormone. In the DAC-bearing version, a maleimide group reacts with a cysteine residue on serum albumin, forming a covalent bond that keeps the peptide in circulation far longer. That albumin attachment is the central design feature separating the two research variants.
Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.
Peptide degradation proceeds mainly through hydrolysis, oxidation of methionine, and deamidation of asparagine or glutamine residues. The maleimide group on the albumin-binding variant can also react with thiols or hydrolyze in aqueous media. Because these pathways accelerate with temperature and pH extremes, handling conditions strongly influence measured stability. Stability data in the public literature are limited and often generated under differing conditions, so general statements about shelf life should be read as approximate.
Research material is normally supplied as a freeze-dried powder in sealed vials. In that state the peptide is comparatively robust, but prolonged exposure to warmth, moisture, or light accelerates degradation. Storage at minus twenty degrees Celsius or lower, with desiccant and protection from light, is the commonly described practice. Vials should be allowed to reach room temperature before opening to limit condensation on the powder. Moisture uptake during handling is a recognized source of variability in later measurements.
| Property | Value | Notes |
|---|---|---|
| Molecular weight (with DAC) | ~3647 Da | Calculated from the full amino acid sequence |
| Molecular weight (without DAC) | ~3368 Da | Mod GRF(1-29) variant |
| Appearance | White lyophilized powder | Typical form supplied for research |
| Solubility | Soluble in water | Dissolves in aqueous buffers |
| Receptor target | GHRH receptor | Expressed on pituitary somatotroph cells |
Lyophilized peptide powder is comparatively stable when kept dry, cold, and protected from light. Once dissolved, the molecule is vulnerable to deamidation, oxidation, and aggregation, with the rate depending on pH, buffer composition, and temperature. Alkaline conditions and repeated freeze-thaw cycles accelerate loss of the intact peptide. The methionine present in the native sequence is a known oxidation site, which is one reason it was replaced in the modified fragment. Suppliers typically recommend cold storage of solutions and use within a short window.
Analytical confirmation usually relies on reversed-phase high-performance liquid chromatography for purity and on liquid chromatography coupled to mass spectrometry for identity. Mass data reveal the expected molecular mass and can flag truncated or oxidized species. Amino acid analysis and peptide mapping provide sequence-level verification. Immunoassays are used in some biological matrices, but antibodies raised against one releasing-hormone analog may cross-react with another. Reported purity figures depend heavily on the method used, so comparisons between suppliers require matching the analytical approach.
The two variants differ dramatically in how long they persist in circulation. The form lacking the albumin-binding group has a plasma half-life measured in tens of minutes, comparable to the natural hormone fragment. The version carrying the drug affinity complex binds albumin and shows a half-life of roughly six to eight days in human studies. That figure comes from small trials that tracked hormone levels over extended periods. The physiological consequences of sustained versus pulsatile stimulation are still debated and the literature does not settle the point.
Identity and purity are established with reversed phase high performance liquid chromatography coupled to mass spectrometry. The chromatographic step separates the target peptide from truncated sequences and deletion products, while the mass measurement confirms the expected molecular weight to within a fraction of a dalton. Because the two common variants differ by the presence of the linker, mass alone can distinguish them in the unconjugated state. Amino acid analysis and peptide mapping are used when sequence level confirmation is required.
Lyophilized material is generally stable for extended periods when held at minus twenty degrees Celsius or below and protected from moisture and light. In solution the peptide is more labile; bond hydrolysis, aggregation and oxidation of susceptible residues all proceed faster at ambient temperature. Repeated freeze and thaw cycles should be avoided because they promote clumping and loss of soluble material. The conjugated variant adds a further consideration, since the maleimide group can hydrolyze in aqueous buffer and lose its ability to react with albumin.
Laboratory handling centers on minimizing exposure to water, heat and oxygen before use. Working solutions are typically prepared in sterile water or a mild buffer, and any residual particulate matter is removed by filtration. When the powder dissolves slowly, a small proportion of acetonitrile or dilute acetic acid is sometimes added as a co-solvent. Containers are kept sealed and desiccated between uses. Records of lot number, reconstitution date and storage conditions support later comparison of results across experiments.
Lyophilized material is typically stored at minus twenty degrees Celsius or lower. Keeping the vial dry and protected from light preserves peptide integrity. Repeated freeze-thaw cycles can cause aggregation or loss of activity. Once dissolved, solutions are generally kept at two to eight degrees Celsius. Stability data for reconstituted solutions vary, and long-term behavior is not fully established. Working aliquots reduce the number of times a stock container is opened.
Reverse-phase high-performance liquid chromatography is the standard tool for purity assessment. The technique separates the target peptide from truncated or modified byproducts. Mass spectrometry confirms molecular weight and supports sequence verification. Electrospray ionization and matrix-assisted laser desorption are both used. Amino acid analysis provides an independent check on composition. Purity values are commonly reported as area percentage from the chromatogram. Residual trifluoroacetate and water content are also measured in many quality programs.
Batch-to-batch consistency depends on solid-phase peptide synthesis and subsequent purification. Coupling efficiency, resin choice, and cleavage conditions all affect the final profile. Counter-ion content and moisture can shift the apparent mass of a batch. Documentation typically includes a certificate of analysis with chromatograms and spectra. Independent verification by a second laboratory is sometimes requested. Whether a given certificate reflects the actual vial contents depends on chain of custody. Analytical methods themselves carry uncertainty that should be stated alongside results.
=== Anime === An anime television series adaptation of the first part was announced on April 10, 2025. It is produced by Wit Studio and directed by Ken Yamamoto, with Kazuhiro Furuhashi serving as animation adviser, Ayumu Hisao handling series composition, Namiko Torii designing the characters, and Kensuke Ushio composing the music. The series aired from March 29 to June 28, 2026 on Tokyo MX and other networks, with an advance screening held on March 15 of the same year at Shinjuku Wald 9 in Tokyo. The opening theme song is "Petals" (ペタルズ, Petaruzu), while the ending theme song is "Hana Ikada" (花筏), both performed by Orangestar featuring Kase. Crunchyroll is streaming the series in simulcast with an English dub. Muse Communication licensed the series in Southeast Asia.
Friendly-fire, which was previously enabled by default, was disabled in the retail version, bleeding - losing small amounts of health over time caused by injuries which "bled" - was removed, and a mini-map was added to more easily facilitate navigation and cooperation between fellow team members. UI improvements, including identifiers for differentiating team members from enemies and help messages that acted as a tutorial for new players, were also introduced in the retail release. At the end of July 2004, Valve shut down its WON authentication servers in favor of their digital distribution service Steam. All of Valve's games using the service were migrated to Steam, forcing players to use the new platform to access Day of Defeat. WON itself continued operating under Sierra/Activision until November 2008. In 2013, Valve released an update for Day of Defeat, alongside other GoldSrc games developed by Valve, which included versions of the game for Mac OS X and Linux.
The duration of estradiol esters in oil solution by intramuscular injection is dose-dependent. With estradiol valerate, it is reported that a dose of 5 mg has a duration of 7 to 8 days, 10 mg a duration of 10 to 14 days, 40 mg a duration of 2 to 3 weeks, and 100 mg a duration of 3 to 4 weeks. High doses of estradiol valerate, such as 40 mg per week, can achieve pregnancy levels of estradiol. A study of pseudopregnancy with intramuscular injections of 40 mg/week estradiol valerate and 250 mg/week hydroxyprogesterone caproate observed estradiol levels of about 2,500 to 3,000 pg/mL.
Sources: en.wikipedia.org
=== Ra === Efraim Racker (1913–1991). Austrian-American biochemist at Cornell University, notable for work on ATP synthase. Member Natl. Acad. Sci. USA. George Radda FRS (1936–2024). Hungarian biochemist at Oxford University, known for applying nuclear magnetic resonance to complex biological material, and many other contributions. Ronald T. Raines (b. 1958). American biochemist at the University of Wisconsin–Madison and MIT, known for work on enzymes and other proteins. Venkatraman Ramakrishnan FRS (President) (b. 1952). Indian-British-American structural biologist at the MRC Laboratory of Molecular Biology, Cambridge, known for work on the ribosome. Nobel Prize in Chemistry in 2009. Philip Randle (1926–2006). British biochemist at the University of Bristol known for work on diabetes. Samuel Mitja Rapoport (1912–2004). Austrian and German biochemist at the Humboldt University, Berlin noted for studies of mitochondria, and for discovering a method for preserving blood for transfusions. Leader of biochemistry in the German Democratic Republic. Member of the German Academy of Sciences at Berlin. Tom Rapoport (b. 1947). German-American cell biologist at Harvard Medical School who studies protein transport in cells.
== Public image == Kardashian has received criticism and negative comments which were focused on her body since Keeping Up with the Kardashians premiered in 2007. She has been compared to her sisters Kourtney and Kim with Kardashian recalling "I didn't really realize that I was 'the fat sister' if you will until I went on TV and the media started saying that about me. I knew I didn't look like my sisters and I didn't have those shapes, but I didn't think that was wrong". Kardashian's physique, notably her face, has attracted significant attention from the media and public in recent years. She has received comments from the public regularly saying she looks "unrecognisable". However, Kardashian has denied having surgery, stating that when she lost weight she lost fat in her face and also credits her make-up artist. She has also been open to using photo editing app Facetune, and stated "Facetune is the best thing to bring to the table. It's life-changing" in February 2016.
== How it works == The LIT uses a set of quadrupole rods to confine ions radially and a static electrical potential on the end electrodes to confine the ions axially. The LIT can be used as a mass filter or as a trap by creating a potential well for the ions along the axis of the trap. The mass of trapped ions may be determined if the m/z lies between defined parameters. Advantages of the LIT design are high ion storage capacity, high scan rate, and simplicity of construction. Although quadrupole rod alignment is critical, adding a quality control constraint to their production, this constraint is additionally present in the machining requirements of the 3D trap.
ABS-201 is an AI-designed monoclonal antibody against the prolactin receptor (PRLR) currently in Phase 1/2a clinical trial for the treatment of androgenic alopecia (pattern hair loss) and endometriosis. It is taken by subcutaneous injection. ABS-201 is a possible first-in-class drug with a novel mechanism of action in the potential treatment of hair loss. ABS-201 is under development by Absci. It is believed that ABS-201 works by activating dormant hair follicles and causing them to move from the telogen phase to the anagen phase. In human ex vivo scalp model studies, ABS-201 stimulated hair regrowth, prolonged anagen phase, blocked catagen phase, inhibited telogen effluvium, and blocked hair from losing color. ABS-201 has been found to produce robust hair regrowth as compared with minoxidil in mice and balding macaques. The clinical trial for ABS-201 is being overseen by prominent hair loss researcher Rodney Sinclair, one of the principal investigators in minoxidil clinical trials. The chemical structure of the drug does not yet appear to have been disclosed.
Sources: en.wikipedia.org
The synthetic peptide keeps the receptor-binding region of GHRH but carries substitutions that resist enzymatic cleavage. In the DAC version, an added group also anchors the molecule to albumin, extending its presence in the bloodstream.
The maleimide group forms a covalent link with albumin, an abundant blood protein. This attachment slows clearance, so a single administration persists much longer than the unmodified peptide. The feature is the main reason the two variants are handled differently in study design.
It is not an approved therapeutic product in major regulatory jurisdictions. It appears in research chemical catalogs and scientific literature rather than pharmacy shelves. Clinical development was limited and did not reach approval.
Cool, dark, and dry conditions are standard, with storage at minus twenty degrees Celsius or below. Desiccant and sealed vials limit moisture uptake. Repeated warming and cooling of the container is generally avoided.